GL1X · GenesisL1 explorer

MolNFT v1 · #145808 · protein

Structure of sphingomyelin in complex with mouse CD1D

6CYW · Antigen-presenting glycoprotein CD1D1: “Structure of sphingomyelin in complex with mouse CD1D”. X-ray diffraction, 2 ligands (FO4, NAG), 4 pockets (best druggability 0.84). MolNFT v1 #145808 on GenesisL1: 3D structure, binding sites…

PDB
6CYW
Type
protein
Length
369 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Antigen-presenting glycoprotein CD1D1; Beta-2-microglobulin
UniProt
A0A0R4J090, P01887
Ligands
FO4, NAG
Pockets
4 · best druggability 0.84

Structure

x-ray diffraction · 2 distinct chains · 19% helix, 45% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AAntigen-presenting glycoprotein CD1D1protein27126% helix, 42% strandA0A0R4J090
BBeta-2-microglobulinprotein980% helix, 52% strandP01887

Ligands and binding sites

  • FO4 · sphingomyelin · ligand · chains A
  • NAG · 2-acetamido-2-deoxy-beta-D-glucopyranose · sugar · 4 copies · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

4 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
16340.840.8858FO4
25000.670.7854empty
31290.440.7617empty
4810.350.7620empty

Interfaces

1 interface between chains.

  • A–B · 1298 Ų buried · 12 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 3 disulfide, 3 glycan (disulfide, N-glycosylation).

Compared structures

  • 6CYW · Structure of sphingomyelin in complex with mouse CD1d · the same entry in another collection · chain A against A, TM-score 1.00
  • P01887 · AlphaFold monomer V2.0 prediction for beta-2-microglobulin (P01887) · a predicted model of the same protein · chain B against A, TM-score 0.97

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.